Methamphetamine and Troriluzole

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
William Stoops
Study ID
NCT06989853
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Methamphetamine Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Placebo — DRUG
    The effects of placebo will be determined.
  • Methamphetamine — DRUG
    Placebo and methamphetamine will be administered intravenously during experimental sessions.

Study Details

This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Key Dates

Start date
Aug 25, 2025
Status verified
Jun 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    Subjects will be treated daily with an oral placebo.
  • Experimental: Troriluzole Dose 1
    Subjects will be treated daily with oral troriluzole (140 mg).
  • Experimental: Troriluzole Dose 2
    Subjects will be treated daily with oral troriluzole (280 mg).

Primary Outcome Measure

Reinforcing Effects of Methamphetamine [ Time Frame: 9 times over approximately 1 month inpatient admission ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Psychopharmacology of Addiction LaboratoryLexingtonKentucky40507
William W Stoops, PhD
[email protected]
859-257-5388
William W Stoops, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lexington, KY

By research site
Psychopharmacology of Addiction Laboratory· Lexington, KY

Related Studies